Drug (ID: DG01908) and It's Reported Resistant Information
Name
DETD-35
Synonyms
DETD-35
    Click to Show/Hide
Target . NOUNIPROTAC [1]
Type(s) of Resistant Mechanism of This Drug
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Melanoma [ICD-11: 2C30]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) [1]
Molecule Alteration Missense mutation
p.V600E (c.1799T>A)
Sensitive Disease Melanoma [ICD-11: 2C30.0]
Experimental Note Revealed Based on the Cell Line Data
Cell Pathway Regulation MEK/ERK signaling pathway Inhibition hsa04011
AKT signaling pathway Inhibition hsa04151
STAT3 signaling pathway Inhibition hsa04550
In Vitro Model A375 cells Skin Homo sapiens (Human) CVCL_0132
MeWo cells Skin Homo sapiens (Human) CVCL_0445
A2058 cells Skin Homo sapiens (Human) CVCL_1059
B16-F10 cells Skin Mus musculus (Mouse) CVCL_0159
SkMEL2 cells Skin Homo sapiens (Human) CVCL_0069
BRAF cells N.A. Homo sapiens (Human) N.A.
In Vivo Model NSG mouse PDX model Mus musculus
Experiment for
Molecule Alteration
Western blotting analysis; Immunohistochemistry analysis
Experiment for
Drug Resistance
MTT assay; Crystal violet staining assay; FACS assay
Mechanism Description DETD-35 overcame acquired vemurafenib resistance at least in part through deregulating MEK-ERK, Akt, and STAT3 signaling pathways and promoting apoptosis of cancer cells.
References
Ref 1 A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in MiceMol Cancer Ther. 2016 Jun;15(6):1163-76. doi: 10.1158/1535-7163.MCT-15-0973. Epub 2016 Apr 5.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.